D. E. Shaw & Co., Inc. Precigen, Inc. Transaction History
D. E. Shaw & Co., Inc.
- $114 Billion
- Q1 2024
A detailed history of D. E. Shaw & Co., Inc. transactions in Precigen, Inc. stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 1,784,886 shares of PGEN stock, worth $2.53 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,784,886
Previous 1,009,447
76.82%
Holding current value
$2.53 Million
Previous $1.35 Million
91.42%
% of portfolio
0.0%
Previous 0.0%
Shares
17 transactions
Others Institutions Holding PGEN
# of Institutions
142Shares Held
145MCall Options Held
208KPut Options Held
43.7K-
Third Security, LLC83.5MShares$119 Million73.5% of portfolio
-
Patient Capital Management, LLC Baltimore, MD17.5MShares$24.8 Million1.27% of portfolio
-
Black Rock Inc. New York, NY10.4MShares$14.7 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.77MShares$9.61 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA3.03MShares$4.3 Million0.0% of portfolio
About PRECIGEN, INC.
- Ticker PGEN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 208,150,000
- Market Cap $296M
- Description
- Precigen, Inc. discovers and develops the next generation of gene and cellular therapies in the United States. It also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; and reproductive and embryo transfer technologies. In addition, the company offers UltraVector platform that incorpora...